Gilead CEO O'Day feels 'sense of urgency' on dealmaking as Kite writedowns add up

Searching for growth back in 2017, Gilead scooped up CAR-T biotech Kite Pharma for $12 billion. Now, write-offs from that buyout are adding up—and new CEO Daniel O'Day is hunting other deals that might deliver a bigger payoff.